5414002026-04-012026-06-305414002026-06-305414002026-04-012026-06-30in-capmkt:OtherExpenses1Member5414002026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15414002026-06-30Statement15414002026-04-012026-06-30Statement15414002026-06-30StatementDynamic1I1Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares541400ZIMLABNOTLISTEDINE518E01015ZIM Laboratories LimitedMain BoardEquity2026-04-012027-03-312026-08-062026-07-31INRLakhsQuarterlyFirst quarterSingle segmentPharmacuetical Industry2026-08-0610:30:002026-08-0616:30:00Not applicabletrue1false1. This note pertains to column asking for "No. of times funds raised during the quarter". We would like to inform you that the Company has raised the funds through prefrential issue in the previous quarter ended 31st March 2026 and no funds were raised during the current quater ended 30th June 2026. <br /> <br /> As there is no option to select "0" or "Not applicable for this quater" and this being the mandatory field, we have selected the no. of times fund raised for this quarter as "1". However, no funds were raised for the reporting quarter. <br /> <br /> 2. The disclosure for the Default on Loan and Debt Securities is not applicable for the said reporting period.2026-04-012026-06-30UnauditedStandalone93048300098550009403380004381610005091000-485870001813690003643400051708000330384000994560000-542220000-542220000-15467000-154670000-387550000000-38755000-245000-3900000053549000010-0.72-0.7200-0.72-0.720.00510.0052-0.0049Notes : <br /> <br /> 1) The above statement of standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 05 August 2026 and 06 August 2026. The above results have been subjected to limited review by Statutory Auditor of the Company. <br /> <br /> 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI). <br /> <br /> 3) The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures for the year ended 31 March 2026 and year to date figures upto 31 December 2025, on which auditors had performed a limited review. <br /> <br /> 4) The Company is principally engaged in a single business segment which is "pharmaceuticals". There is no separate reportable segment as per Ind AS 108 - Operating Segments. <br /> <br /> <br /> <br /> <br /> <br /> <br /> Other Expenses330384000Measurement of defined employee benefit plans-346000-346000-1010000-245000Preferential Issues2026-03-13349999949620002026-06-30falsefalsePiyush NikhadeCompany Secretary and Compliance OfficerNagpur2026-08-06000000This is to inform that the Company has raised funds through preferential issue during the previous quarter ended 31st March 2026. Company has not raised any funds during the reporting quater ended 30th June, 2026 and in this quarter there is no deviation or Variation in the utilisation of the fund raised.